The company plans to establish similar healthcare centres across universities, schools, and corporate campuses nationwide
Crucially, Lupin is the exclusive first-to-file applicant for this product and is eligible for 180-day generic drug exclusivity in the U.S. market
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
AI-enabled technology platform delivers integrated pharmacovigilance solutions with measurable efficiency gains and enhanced compliance
Company to highlight science-backed actives, nature-powered ingredients, and its new “Natural by Barentz” private label platform in Barcelona
Acquisition enhances integrated pharmacovigilance platform, combining AI, automation, and services to improve compliance, efficiency, and end-to-end clinical safety operations
Postdoctoral fellowship aims to build skilled talent pool in biotechnology and life sciences
Subscribe To Our Newsletter & Stay Updated
